• 1
    Sephton S, Spiegel D. Circadian disruption in cancer: a neuroendocrine-immune pathway from stress to disease? Brain Behav Immun. 2003; 17: 321-328.
  • 2
    Touitou Y, Bogdan A, Levi F, Benavides M, Auzeby A. Disruption of the circadian patterns of serum cortisol in breast and ovarian cancer patients: relationships with tumour marker antigens. Br J Cancer. 1996; 74: 1248-1252.
  • 3
    Touitou Y, Levi F, Bogdan A, Benavides M, Bailleul F, Misser J-L. Rhythm alteration in patients with metastatic breast cancer and poor prognostic factors. J Cancer Res Clin. 1995; 121: 181-188.
  • 4
    Bower JE, Ganz PA, Dickerson SS, Petersen L, Aziz N, Fahey JL. Diurnal cortisol rhythm and fatigue in breast cancer survivors. Psychoneuroendocrinology. 2005; 30: 92-100.
  • 5
    Sephton S, Sapolsky RM, Kraemer HC, Speigel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst. 2000; 92: 994-1000.
  • 6
    Buijs RM, van Eden CG, Goncharuk VD, Kalsbeek A. Circadian and season rhythms: the biological clock tunes the organs of the body: timing by hormones and the autonomic nervous system. J Endocrinol. 2003; 177: 17-26.
  • 7
    Kirschbaum C, Hellhammer DH. Salivary cortisol. In: FinkG, ed. Encyclopedia of Stress. Vol 3. Burlington, MA: Academic Press; 2000.
  • 8
    Maier S, Watkins L. Cytokines for psychologists: implications of bidirectional immune to brain communication for understanding behavior, mood, and cognition. Psychol Rev. 1998; 105: 83-107.
  • 9
    Kirschbaum C, Hellhammer DH. Salivary cortisol in psychobiological research: an overview. Neuropsychobiology. 1989; 22: 150-169.
  • 10
    Smyth J, Ockenfels M, Gorin A, et al. Individual differences in the diurnal cycle of cortisol. Psychoneuroendocrinology. 1997; 22: 89-105.
  • 11
    Sapolsky RM, Alberts SC, Altmann J. Hypercortisolism associated with social subordinance or social isolation among wild baboons. Arch Gen Psychiatry. 1997; 54: 1137-1143.
  • 12
    Chrousos GP, Gold PW. A healthy body in a healthy mind-and vice versa-the damaging power of “uncontrollable” stress. J Clin Endocrinol Metab. 1998; 83: 1842-1845.
  • 13
    Deuschle M, Schweiger U, Weber B, et al. Diurnal activity and pulsatility of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls. J Clin Endocrinol Metab. 1997;82:234238.
  • 14
    Jehn CF, Kuehnhardt D, Bartholomae A, et al. Biomarkers of depression in cancer patients. Cancer. 2006; 107: 2723-2729.
  • 15
    Turner-Cobb J, Sephton S, Koopman C, Blake-Mortimer J, Spiegel D. Social support and salivary cortisol in women with metastatic breast cancer. Psychosom Med. 2000; 62: 337-345.
  • 16
    Sapolsky RM, Donnelly TM. Vulnerability to stress-induced tumor growth increases with age in rats: role of glucocorticoids. Endocrinology. 1985; 117: 662-666.
  • 17
    Filipski E, King VM, Li X, et al. Host circadian clock as a control point in tumor progression. J Natl Cancer Inst. 2002; 94: 690-697.
  • 18
    Schernhammer ES, Laden F, Speizer FE, et al. Rotating night shifts and risk of breast cancer in women participating in nurses' health study. J Natl Cancer Inst. 2001; 93: 1563-1568.
  • 19
    Mormont MC, Levi F. Circadian-system alterations during cancer processes: a review. Int J Cancer. 1997; 70: 241-247.
  • 20
    Lutgendorf SK, Weinrib AZ, Penedo F, et al. Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J Clin Oncol. 2008; 26: 4820-4827.
  • 21
    Thakore JH, Barnes C, Joyce J, Medbak S, Dinan TG. Effects of anti-depressant treatment on corticotropin-induced cortisol responses in patients with melancholic depression. Psychiatry Res. 1997; 73: 27-32.
  • 22
    Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Ovarian. J Clin Oncol. 2001; 19: 1809-1817.
  • 23
    Gynecologic Oncology Group Protocol Procedures Manual. Appendix 10. November 2005.
  • 24
    McNair DM, Lorr M, Droppelman LF. EdiTS Manual for the Profile of Mood States. San Diego, CA: EITS; 1992.
  • 25
    Andersen B, Anderson B, deProsse C. Controlled prospective longitudinal study of women with cancer: I. Psychological functioning and outcomes. J Consult Clin Psychol. 1989; 57: 683-691.
  • 26
    Radloff L. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977; 1: 385-401.
  • 27
    Sheehan TJ, Fifield J, Reisine S, Tennen H. The measurement structure of the Center for Epidemiologic Studies depression scale. J Pers Assess. 1995; 64: 507-521.
  • 28
    Cohen S, Kamarck T, Mermelstein R. Global measure of perceived stress. J Health Hum Behav. 1983; 24: 385-396.
  • 29
    Stone AA, Mezzacappa E, Donatone B, Gonder M. Psychosocial stress and social support are associated with prostate-specific antigen levels in men: results from a community screening program. Health Psychol. 1999; 18: 482-486.
  • 30
    Sarason IG, Johnson JH, Siegel JM. Assessing the impact of life changes: development of the Life Experiences Survey. J Consult Clin Psychol. 1978; 46: 932-946.
  • 31
    Leserman J, Whetten K, Lowe K, Stangl D, Swartz MS, Thielman NM. How trauma, recent stressful events, and PTSD affect functional health status and health utilization in HIV-infected patients in the south. Psychosom Med. 2005; 67: 500-507.
  • 32
    Kraemer HC, Giese-Davis J, Yutsis M, et al. Design decisions to optimize reliability of daytime cortisol slopes in an older population. Am J Geriatr Psychiatry. 2006; 14: 325-333.
  • 33
    Giese-Davis J, Wilhelm FH, Conrad A, et al. Depression and stress reactivity in metastatic breast cancer. Psychosom Med. 2006; 68: 675-683.
  • 34
    Deuschle M, Gotthardt U, Schweiger U, et al. With aging in humans the activity of the hypothalamus-pituitary-adrenal system increases and its diurnal amplitude flattens. Life Sci. 1997; 61: 2246-2249.
  • 35
    Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986; 73: 13-22.
  • 36
    File SE. Interactions of anxiolytic and antidepressant drugs with hormones of the hypothalamic-pituitary-adrenal axis. Pharmacol Ther. 1990; 46: 357-395.
  • 37
    Skelton KH, Nemeroff CB, Knight DL, Owens MJ. Chronic administration of the triazolobenzodiazepine alprazolam produces opposite effects on corticotropin-releasing factor and urocortin neuronal systems. J Neurosci. 2000; 20: 1240-1248.
  • 38
    Abercrombie HC, Giese-Davis J, Sephton S, Epel ES, Turner-Cobb JM, Spiegel D. Flattened cortisol rhythms in metastatic breast cancer patients. Psychoneuroendocrinology. 2004; 29: 1082-1092.
  • 39
    Raison CL, Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry. 2003; 160: 1554-1565.
  • 40
    McCain GA, Tilbe KS. Diurnal hormone variation in fibromyalgia syndrome: a comparison with rheumatoid arthritis. J Rheumatol. 1989(19 suppl): 154-157.
  • 41
    Nater UM, Youngblood LS, Jones JF, et al. Alterations in diurnal salivary cortisol rhythm in a population-based sample of cases with Chronic Fatigue Syndrome. Pyschosomatic Medicine. 2008; 70: 298-305.
  • 42
    Baxter JD, Frohman LA, Felig P. Introduction to the endocrine system. In: FeligP, BaxterJD, FrohmanLA, eds. Endocrinology and Metabolism. 3rd ed. New York, NY: McGraw-Hill; 1995: 3-20.
  • 43
    Spiegel D, Giese-Davis J, Taylor CB, Kraemer H. Stress sensitivity in metastatic breast cancer: analysis of hypothalamic-pituitary-adrenal axis function. Psychoneuroendocrinology. 2006; 31: 1231-1244.
  • 44
    Watson JM, Sensintaffar JL, Berek JS, Martinez-Maza O. Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res. 1990; 50: 6959-6965.
  • 45
    Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med. 1995; 332: 1351-1362.
  • 46
    Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008; 9: 46-57.
  • 47
    Hughes JW, Watkins L, Blumenthal JA, Kuhn C, Sherwood A. Depression and anxiety symptoms are related to increased 24-hour urinary norepinephrine excretion among healthy middle-aged women. J Psychosom Res. 2004; 57: 353-358.
  • 48
    Nilsson MB, Armaiz-Pena G, Takahashi R, et al. Stress hormones regulate IL-6 expression by human ovarian carcinoma cells through a SRC-dependent mechanism. J Biol Chem. 2007; 282: 29919-29926.
  • 49
    Cavadini G, Petrzilka S, Kohler P, et al. TNF-alpha suppresses the expression of clock genes by interfering with E-box-mediated transcription. Proc Natl Acad Sci U S A. 2007; 104: 12843-12848.
  • 50
    Ohdo S, Koyanagi S, Suyama H, Higuchi S, Aramaki H. Changing the dosing schedule minimizes the disruptive effects of interferon on clock function. Nat Med. 2001; 7: 356-360.
  • 51
    Kronfol Z, Nair M, Zhang Q, Hill EE, Brown MB. Circadian immune measures in healthy volunteers: relationship to hypothalamic-pituitary-adrenal axis hormones and sympathetic neurotransmitters. Psychosom Med. 1997; 59: 42-50.
  • 52
    Sephton SE, Dhabhar FS, Keuroghlian AS, et al. Depression, cortisol, and suppressed cell-mediated immunity in metastatic breast cancer. Brain Behav Immun. 2009; 23: 1148-1155.
  • 53
    Mormont M-C, Hecquet B, Bogdan A, Benavides M, Touitou Y, Levi F. Non-invasive estimation of the circadian rhythm in serum cortisol in patients with ovarian or colorectal cancer. Int J Cancer. 1998; 78: 421-424.
  • 54
    Levi F. Circadian chronotherapy for human cancers. Lancet. 2001; 2: 307-315.
  • 55
    Moran TJ, Gray S, Mikosz CA, Conzen SD. The glucocorticoid receptor mediates a survival signal in human mammary epithelial cells. Cancer Res. 2000; 60: 867-872.
  • 56
    Antonova L, Mueller CR. Hydrocortisone down-regulates the tumor suppressor gene BRCA1 in mammary cells: a possible molecular link between stress and breast cancer. Genes Chromosomes Cancer. 2008; 47: 341-352.
  • 57
    Pang D, Kocherginsky M, Krausz T, Kim SY, Conzen SD. Dexamethasone decreases xenograft response to Paclitaxel through inhibition of tumor cell apoptosis. Cancer Biol Ther. 2006; 5: 933-940.
  • 58
    Johansson AC, Gunnarsson LG, Linton SJ, et al. Pain, disability and coping reflected in the diurnal cortisol variability in patients scheduled for lumbar disc surgery. Eur J Pain. 2008; 12: 633-640.